Applied health economics and health policy
-
Appl Health Econ Health Policy · Nov 2011
Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially fatal disease. Little is known about the economic burden associated with CTEPH patients in the US. ⋯ CTEPH patients had substantially higher costs and co-morbidity than matched controls, with circulatory-/respiratory-related costs accounting for 55% of excess costs. The high burden of illness suggests opportunities for savings from improved management.